Trial Profile
Phase II, Multicenter, Randomized, Double-blind, Placebo Controlled Study to Assess Safety and Efficacy of TRO40303 for Reduction of Reperfusion Injury in Patients Undergoing Percutaneous Coronary Intervention for Acute Myocardial Infarction
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs TRO 40303 (Primary)
- Indications Myocardial infarction; Myocardial reperfusion injury
- Focus Proof of concept; Therapeutic Use
- Acronyms MITOCARE
- Sponsors Trophos
- 01 Sep 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 15 Mar 2013 Planned End Date changed from 1 Jun 2013 to 1 Aug 2013 as reported by ClinicalTrials.gov.
- 27 Dec 2012 Planned end date changed from 1 Oct 2012 to 1 Jun 2013 as reported by ClinicalTrials.gov.